One of the main points of focus for analysts at an R&D briefing by Sumitomo Dainippon Pharma Co. Ltd. (SDP) in Japan last month was an innovative molecule for schizophrenia developed by the Japanese firm’s US affiliate Sunovion Pharmaceuticals Inc. and now moving through late pivotal trials.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?